Advances With CAR T-Cell Therapy in Multiple Myeloma

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss how agents such as cilta-cel and ide-cel have affected multiple myeloma management.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, explain the role of treatment center coordinators in CAR T-cell therapy administration in multiple myeloma.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail current expectations with manufacturing processes for CAR T-cell therapy.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss considerations for bridging therapy ahead of CAR T-cell therapy in multiple myeloma.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, detail data for out-of-specification cilta-cel in multiple myeloma, as presented at ASH 2025.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss other key CAR T-cell therapy updates to emerge from the 2025 ASH Annual Meeting.

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, discuss future research directions for CAR T-cell therapy in multiple myeloma.